About Careers MedBlog Contact us

Cancer Patients may Benefit From MicroRNA

by Vani Pradeep on December 9, 2014 at 11:58 AM
Font : A-A+

Cancer Patients may Benefit From MicroRNA

In many cancers, including ovarian and breast cancers, one of the most frequent chromosomal aberrations is a genetic misfire called 3q26.2 amplicon. This can cause real havoc.

Researchers behind a study at The University of Texas MD Anderson Cancer Center believe they may have found a molecule-based approach to halting 3q26.2's destructive nature. By manipulating a non-coding microRNA (miRNA) known as miR569 that is part of the amplicon, scientists were able to increase cell death in vitro and in vivo. MicroRNAs are short, non-coding RNA molecules that are important to controlling gene expression.


The study was featured in this month's issue of Cancer Cell. "Small non-coding miRNAs represent underexplored targets of genetic aberrations and emerging therapeutic targets," said study lead Gordon Mills, M.D., Ph.D., professor and chair of Systems Biology at MD Anderson. "We demonstrated that miR569, which is overexpressed in a subset of ovarian and breast cancers due in part to the 3q26.2 amplicon, can impact cell survival and proliferation."

In order for miR69 to halt 3q26.2's penchant for molecular mayhem, it must first alter expression levels of the tumor protein known as TP53INP1.

"The study results clearly show that TP53INP1 is a key target of miR569 both in vitro and in vivo," said Mills. "An increase in miR569 levels subsequently decreased TP53INP1 levels which was associated with worsened outcomes for ovarian patients."

However, when miR569 expression was "silenced" or decreased, TP53INP1 levels were increased and survivability outcomes improved. In effect, targeting miR569 sensitizes ovarian and breast cancer cells overexpressing miR569 to the commonly used chemotherapy agent cisplatin, which impacts its effectiveness.

"The discovery that miRNAs are potent regulators of RNA stability and translation dramatically change our understanding of the mechanisms controlling protein levels, and further provided a therapeutic approach to a number of targets that have previously been designated as 'undruggable'," said Mills.

Source: Eurekalert


Recommended Reading

Latest Cancer News

Is Adding Ribociclib to Hormone Therapy Improves Breast Cancer Outcomes
HR positive/HER2 negative breast cancer is the most common subtype of the disease and accounts for nearly 70% of breast cancer cases in the Unites States.
Antibody Treatment Proves Effective for Bile Duct Cancers
An antibody treatment helped shrink tumors in some patients with bile duct cancers.
Link Between Gut Microbiome and Precancerous Colon Polyps Identified
Comprehending the association between the gut microbiome and polyp growth sheds insights into potential screenings and treatments.
 Analyzing Paediatric Brain Tumours Provide Data for Cancer Research
The first large-scale, collaborative, open analysis of genomic data provides a cloud-based resource for researchers looking for more comprehensive data on pediatric brain tumors.
Cancer Drugs to be Tested in Orbit During American Private Astronaut Mission
The mission of Axiom Space incorporated numerous experiments focusing on human stem cell aging, inflammation, and cancer within the laboratory situated in the low Earth orbit.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Cancer Patients may Benefit From MicroRNA Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests